JPWO2023099622A5 - - Google Patents
Info
- Publication number
- JPWO2023099622A5 JPWO2023099622A5 JP2024532418A JP2024532418A JPWO2023099622A5 JP WO2023099622 A5 JPWO2023099622 A5 JP WO2023099622A5 JP 2024532418 A JP2024532418 A JP 2024532418A JP 2024532418 A JP2024532418 A JP 2024532418A JP WO2023099622 A5 JPWO2023099622 A5 JP WO2023099622A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- tcr
- fusion molecule
- range
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163285044P | 2021-12-01 | 2021-12-01 | |
| US63/285,044 | 2021-12-01 | ||
| US202263374222P | 2022-08-31 | 2022-08-31 | |
| US63/374,222 | 2022-08-31 | ||
| PCT/EP2022/083952 WO2023099622A1 (en) | 2021-12-01 | 2022-11-30 | Treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024542682A JP2024542682A (ja) | 2024-11-15 |
| JP2024542682A5 JP2024542682A5 (https=) | 2025-12-08 |
| JPWO2023099622A5 true JPWO2023099622A5 (https=) | 2025-12-08 |
Family
ID=84688213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024532418A Pending JP2024542682A (ja) | 2021-12-01 | 2022-11-30 | 治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250333504A1 (https=) |
| EP (1) | EP4441096A1 (https=) |
| JP (1) | JP2024542682A (https=) |
| KR (1) | KR20240114759A (https=) |
| AU (1) | AU2022402322A1 (https=) |
| IL (1) | IL312981A (https=) |
| MX (1) | MX2024006799A (https=) |
| TW (1) | TW202330589A (https=) |
| WO (1) | WO2023099622A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202519257A (zh) | 2023-08-01 | 2025-05-16 | 英商英美偌科有限公司 | 治療皮膚黑色素瘤之方法 |
| TW202544042A (zh) | 2024-03-13 | 2025-11-16 | 英商英美偌科有限公司 | 治療prame陽性癌症之方法 |
| WO2025224692A1 (en) | 2024-04-25 | 2025-10-30 | Immunocore Limited | Method of treating cancer using a gene expression signature |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002321581C1 (en) | 2001-08-31 | 2008-09-18 | Adaptimmune Limited | Soluble T cell receptor |
| GB201223172D0 (en) | 2012-12-21 | 2013-02-06 | Immunocore Ltd | Method |
| WO2017208018A1 (en) * | 2016-06-02 | 2017-12-07 | Immunocore Limited | Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein |
| GB201709866D0 (en) | 2017-06-20 | 2017-08-02 | Immunocore Ltd | T cell receptors |
-
2022
- 2022-11-30 KR KR1020247021027A patent/KR20240114759A/ko active Pending
- 2022-11-30 IL IL312981A patent/IL312981A/en unknown
- 2022-11-30 AU AU2022402322A patent/AU2022402322A1/en active Pending
- 2022-11-30 EP EP22830692.4A patent/EP4441096A1/en active Pending
- 2022-11-30 MX MX2024006799A patent/MX2024006799A/es unknown
- 2022-11-30 US US18/716,126 patent/US20250333504A1/en active Pending
- 2022-11-30 JP JP2024532418A patent/JP2024542682A/ja active Pending
- 2022-11-30 WO PCT/EP2022/083952 patent/WO2023099622A1/en not_active Ceased
- 2022-12-01 TW TW111146224A patent/TW202330589A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025016606A5 (https=) | ||
| JP2020521797A5 (https=) | ||
| US20230303678A1 (en) | Methods for treatment of subjects with plaque psoriasis of the scalp | |
| JP2021514354A5 (https=) | ||
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2019532970A5 (https=) | ||
| WO2025061123A1 (zh) | 治疗非霍奇金淋巴瘤的药物组合及其用途 | |
| Gu et al. | Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia | |
| JP6034314B2 (ja) | Ｂ細胞リンパ腫の治療における放射線標識化抗ｃｄ２０抗体を使用する組合わせ治療 | |
| TW202535468A (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JP2024028756A5 (https=) | ||
| WO2020236668A1 (en) | Leukadherin-1 alone or in combination for use in the treatment of cancer | |
| JPWO2023099622A5 (https=) | ||
| JPWO2022240688A5 (https=) | ||
| CN115698076A (zh) | 用于治疗肿瘤的药物 | |
| EP3703819A1 (en) | Method of treating tendinopathy using interleukin-17 (il-17) antagonists | |
| CN115779094A (zh) | 癌症联合治疗的组合物与方法 | |
| JP7410256B2 (ja) | 化膿性汗腺炎の治療のための汎ｅｌｒ＋ｃｘｃケモカイン抗体 | |
| RU2024113563A (ru) | Лечение | |
| AU2023270497A1 (en) | Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists | |
| JPWO2021209356A5 (https=) | ||
| US20250019441A1 (en) | Treatment of cancer with anti-ilt2 antibodies | |
| WO2024231875A1 (en) | Hpk1 inhibitor for use in the treatment of cancer | |
| CN120605325A (zh) | 靶向her2的抗原结合构建体与小分子药物联合治疗乳腺癌的用途 | |
| WO2025201522A1 (zh) | 抗Nectin-4抗体药物偶联物治疗肿瘤 |